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Abstract
Multifunctional membrane-core nanoparticles, composed of calcium phosphate cores, arginine-
rich peptides, cationic and PEGylated lipid membranes, and galactose targeting ligands, have been
developed as synthetic vectors for efficient nuclear delivery of plasmid DNA and subsequent gene
expression in hepatocytes in vivo. Targeted particles exhibited rapid and extensive hepatic
accumulation and were predominantly internalized by hepatocytes, while the inclusion of such
peptides in LCP was sufficient to elicit high degrees of nuclear translocation of plasmid DNA.
Monocyclic CR8C significantly enhanced in vivo gene expression over ten-fold more than linear
CR8C, likely due to a release-favoring mechanism of the DNA/peptide complex. Though 100-fold
lower in activity than that achieved via hydrodynamic injection, this formulation presents as a
much less invasive alternative. To our knowledge, this is the most effective synthetic vector for
liver gene transfer.
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Despite significant advantages in loading, targeting, and safety, among others, provided by
synthetic vectors for gene delivery, they still do not compare well with viral vectors in terms
of delivery efficiency.1–5 A variety of polymeric,6–8 liposomal,9, 10 protein-based,11, 12
organic,13, 14 and inorganic15, 16 materials have been developed to incorporate certain viral
characteristics, and vector platforms which can cohesively integrate multiple functionalities
present the greatest potential utility.17 The needs in artificial virus development for DNA
delivery have been outlined previously;3 briefly, therapeutic loading, stability and longevity
in vascular transit, distribution to and uptake into the cells of interest, endosomal escape,
intracellular trafficking, nuclear import, and transcriptional promotion and lifespan must be
rationally considered in effective vector design.
The hepatocytes of the liver present as desirable gene therapy targets for a variety of disease
states,5, 18 including Wilson Disease,19 α1-Antitrypsin Deficiency,20 viral hepatitis,5 and
Factor VII Deficiency,21 primarily due to systemic accessibility, the highly endocytic nature
of hepatocytes, and the potential for high degrees of tissue exposure based on organ
physiology.5 The hepatic sinusoidal epithelium acts as the primary structural and functional
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barrier to hepatocyte exposure, with fenestrations (numbering 8.7±0.5/Im2 with an average
diameter of 141±10.8 nm in C57BL/6 mice) patrolled by a large population of resident
immune cells (e.g. Kupffer cells).22, 23 Typically, formulations employ a dense coating of
antifouling agents such as polyethylene glycol (PEG) to both increase circulation longevity
and limit alternative cell uptake, as well as active targeting strategies to promote uptake by
hepatocytes; sugars such as galactose24, 25 and N-acetylgalactosamine8 have been studied
extensively in this regard for uptake via the asialoglycoprotein receptor (ASGPR).
Upon internalization into endosomes, the contents of the delivery vehicle must escape to
avoid lysosomal sequestration, a process typically achieved by bufferinginduced osmotic
bursting,26 cationic lipid-mediated ion-pair formation,27 or various other endosomolytic
molecules.10, 28 After release, however, trafficking to the nucleus and nuclear import must
still be mediated. Interest has been shown in a variety of oligopeptide species employing
high densities of cationic charge (lysine,29 arginine,30, 31 and histidine32 residues), either
alone or in concert with nuclear localization sequences, to support nuclear translocation;
specifically, arginine-rich bioreducible polymers and polypeptides have been explored in
vitro29, 30 and in vivo17, 33 as efficacious and nontoxic transfection systems. However,
extensive vesicular entrapment of arginine-rich materials has been suggested as the primary
inefficiency of their use in DNA delivery.34
With such studies in mind, we have developed membrane-core nanoparticles (LCP) inspired
by rational design, integrating calcium phosphate nanoprecipitate (CaP) cores, cysteine-
flanked octaarginine peptides (CR8C, Figure s1), and asymmetric lipid membranes35
(densely coated with PEG and targeted via galactose ligands) together to achieve surprising
levels of gene expression within hepatocytes in vivo through intravenous injection in a non-
hydrodynamic manner. Targeted LCP distributed rapidly and extensively to the liver and
was predominantly internalized by hepatocytes, while the inclusion of such peptides in LCP
was sufficient to promote high degrees of nuclear translocation and expression of plasmid
DNA. Interestingly, co-delivery with monocyclic CR8C significantly enhanced in vivo gene
expression over ten-fold more than linear CR8C, possibly due to differences in the degree of
peptide-DNA condensation and dissociation upon release. Based on our exploration of the
current literature, our formulation presents as the most effective synthetic vector for liver
gene transfer.
Results and Discussion
Representative multifunctional features of the membrane-core LCP structures are shown in
Figure 1A. A reverse microemulsion established by a strong surfactant (IGEPAL-520) is
utilized to prepare small, DOPA-coated CaP nanoparticles (LCP “cores”) which can
encapsulate both DNA (appx. 50% efficiency) and peptides, with core size ranging from 20–
30 nm in diameter.35 The hollow core structure can be visualized under TEM (Figure 1B).
Further, the DOPA monolayer surrounding the CaP core allows for the confined assembly of
outer leaflet lipids (DOTAP, cholesterol, DSPE-PEG2000), producing sub-100 nm particles
(“final” LCP, 40–60 nm in diameter, shown in Figure 1C) which can easily penetrate hepatic
sinusoidal fenestrations. PEGylation of LCP was confirmed by a fluorescence method, in
separation from micelles via sucrose gradient centrifugation, to be 20 mol% of outer leaflet
lipids (data not shown). The hydrodynamic diameter and the surface charge of the LCP
particles are outlined in Table 1. Dynamic light scattering indicated that LCP was narrowly
dispersed around 55 nm in diameter, with a near-neutral zeta potential (around +9 mV) due
to charge shielding by PEGylation.
LCP was radiolabeled with 111In during the preparation of CaP core in a similar manner to
previously published methods36 and intravenously injected into C57BL/6 female mice to
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examine its distribution in vivo. Quantitative pharmacokinetic and biodistribution analyses
of 111In-labeled LCP indicated that galactose-targeted LCP distributed rapidly and primarily
to the liver (Figure 2 and Table 2), with 48 ± 1% injected dose (ID) recovered in the liver at
6 h post-injection. In comparison, 16 ± 4% and 29 ± 4% ID were recovered 6 h post-
injection in the liver and the spleen, respectively, in mice treated with untargeted LCP.
Targeting via galactose likely altered the LCP distribution profile due to increased uptake
through ASGPR-mediated endocytosis, as opposed to relying upon cationic lipid-mediated
cellular interactions facilitated by PEGylation shedding from LCP in the circulation.37 Such
a perspective is supported by the increased (3-fold) degree of liver distribution, decreased
(4-fold) distribution half-life, and increased in vitro hepatocyte uptake (Figure s2) associated
with the galactosylated particles.
The synergistic function of the cationic lipids and the acid-sensitive CaP in the lysis of the
endosome has been described previously for LCP;35 however, effective nuclear import still
presents as a significant challenge toward establishing efficacy, especially in
nonproliferative cells such as hepatocytes. Viral vectors typically employ nuclear
localization sequences (NLS) for translocation of genetic material, which are readily
recognized by the cellular nuclear transport machinery.38 In terms of cellular uptake,
octaarginine mimics the NLS of the HIV-1 Tat protein (Tat-(48–60));10, 39–41 however, on a
post-endosomal basis, its utility has not been fully characterized. In order to examine their
effects on the intracellular distribution of the delivered DNA in the liver, Cy3-labeled DNA
was encapsulated in different formulations of LCP (with linear CR8C (l-CR8C), with
monocyclic CR8C (mc-CR8C), or without CR8C) and intravenously injected into C57BL/6
female mice. Livers were harvested 6 h post-administration, and their cryo-sections were
observed by confocal microscopy after staining actin and nuclei. LCP encapsulating no
CR8C was taken up into most of the hepatocytes in the liver; however, the majority of the
Cy3-DNA distributed homogeneously in the cytoplasm (Figure 3). Co-encapsulation with
either mc-CR8C or l-CR8C elicited extensive Cy3-DNA distribution to the hepatocyte
nuclei, strongly suggesting that the arginine-rich peptides could mediate delivery of DNA
into the nucleus. In vitro study further supported the efficient nuclear delivery of Cy3-DNA
by co-encapsulation with such peptides in LCP, with more than 90% of nuclei presenting
strong Cy3 fluorescence (Figure s3). Such extensive uptake into hepatocytes in vivo is likely
supported in part by effective mononuclear phagocyte evasion as well; our lab has recently
shown extensive evasion of Kupffer cell uptake by LCP at higher densities of outer leaflet
lipid PEGylation (greater than 10–15 mol%).42 The most powerful non-viral method,
hydrodynamic (HD) injection,43 was used as a positive control to deliver Cy3-DNA to the
liver. Fluorescence was observed in this case to be punctate and largely confined to the
cytoplasm, with a minor amount accumulating in hepatocyte nuclei.
Plasmids encoding tdTomato red fluorescence protein (RFP) or firefly luciferase (Luc)
driven by the cytomegalovirus promoter were then used respectively as semiquantitative and
quantitative reporter genes by which to characterize LCP as a vector in mice. Expression and
activity were evaluated at 24 h post-injection, and analysis of major organs confirmed
predominant hepatic transgene expression (Figure 4). Interestingly, gene expression was
relatively low in the spleen despite extensive accumulation of LCP on a %ID/gram basis;
such particles likely possess limited ability to internalize into splenocytes. ASGPR-targeting
of LCP via galactose proved effective in increasing both RFP and luciferase expression
(Figure 4), as did targeted co-delivery with mc-CR8C peptide, which increased gene
expression 200-fold over targeted LCP containing no peptide. Further, co-delivery with mc-
CR8C both dramatically increased RFP expression and significantly increased luciferase
expression (4.6*107 RLU/mg protein at a 0.3 mg DNA/kg dose) in the liver over l-CR8C.
Since the two peptides were not observably different in supporting the nuclear import of
plasmid DNA (Figure 3), such differences in reporter gene expression may involve
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differences in peptide-mediated plasmid condensation and release. It has been reported that
excessive strength in DNA complexation by peptide-based condensing agents can both limit
intracellular release and reduce overall efficacy,44 often on structural and sequence-specific
bases.45 Likely supported by a greater conformational flexibility, l-CR8C more readily
condensed plasmid DNA than mc-CR8C, as shown by an enhanced ability to exclude DNA-
SYBR Green fluorescence (Figure 5a) and a more limited dissociation profile in the
presence of anionic materials such as hyaluronan (Figure 5b). Further, the uneven
fluorescence distribution in the nuclei (Figure 3) suggests that the DNA was still bound in
rigid complexes, which could hinder DNA trafficking and transcription within the nuclei.
Our HD comparator supports such a perspective as well; although HD injection delivers less
DNA overall to the nuclei (Figure 3), all of such DNA would be free for transcription.
Notably, our results present a step toward the outperformance of HD injection; though 100-
fold lower in gene expression, our system presents a greatly decreased invasiveness in its
application.
Our gene delivery system compares favorably against a variety of synthetic vectors on the
basis of luciferase activity in vivo. For example, intratumoral injection of poly(amine-co-
ester)-DNA complexes (0.5 mg DNA/kg) at best elicited luciferase activity on the order of
105 RLU/mg protein despite a simplified delivery process.46 Hepatic luciferase activity of
7.5*105 RLU/mg protein was observed after intravenous administration of a galactose-
conjugated bifunctional dendrimer (2.5 mg DNA/kg).47 The optimal linear, cationic polymer
from a small azide-alkyne click library supported gene expression in a subcutaneous tumor
relative to 106 RLU/mg protein when dosing intravenously at 2 mg DNA/kg.48 Alkylated
(ethyl) polyethyleneimine (PEI) produced similar results as well in intravenous delivery to
the lungs (2.5 mg DNA/kg).49 One of the best direct comparisons, however, can be made to
the pH-sensitive and octaarginine-modified MEND delivery system, which elicited hepatic
luciferase activity of appx. 1.3*106 RLU/mg protein after intravenous injection at 2.5 mg
DNA/kg.10 Scaling linearly for activity and dose, targeted mc-CR8C-containing LCP likely
outperforms MEND by roughly 300-fold. Certain design aspects of LCP likely prove
beneficial over MEND-type nanoparticles. The smaller size of LCP (55 nm, vs. 185 nm for
the optimized R8-GALA-MEND) may allow for easier penetration through the hepatic
sinusoidal fenestrations, allowing increased formulation exposure on a per-cell basis.
Intracellular release from PEI, the DNA condensing agent in the MEND formulation, may
be limited in comparison to calcium phosphate core degradation.35 The high intracellular
calcium conditions produced by our formulation may aid in endosomal release as well.50
Further, establishing the octaarginine peptide within the nanoparticle core may better
promote DNA delivery on a post-endosomal basis.
Systemic toxicity and cytokine induction of LCP was investigated 24 h after intravenous
administration to C57BL/6 mice as well. There were no obvious histological differences
between the major organs of treated and untreated mice (Figure 6), and hematological
markers remained relatively unperturbed; however, a notable increase in TNF-α was
observed (Table 3). Further analysis will be required to determine the significance, if any, of
such a response.
Conclusions
We have developed membrane-core LCP nanoparticles that address a variety of the needs in
DNA delivery, integrating together DOPA-coated CaP cores, octaarginine peptides, cationic
and PEGylated lipids, and galactose targeting ligands to achieve high levels of gene
expression in vivo (Scheme 1). The strength and stability of such cores under physiological
conditions confer the desired protection against degradation in circulation while supporting
both an asymmetric and a highly functionalized lipid bilayer. Such a formulation can
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efficiently encapsulate DNA as a relatively small vector which presents as ideal in size and
PEGylation for delivery to hepatocytes in vivo. Further, ASGPR-targeting via galactose
supports increased and rapid distribution to the liver, presumably through an increased rate
of internalization of LCP. Such particles have shown to be effective in cytosolic release of
DNA, and co-delivery with the cationic peptides CR8C supports extensive nuclear
translocation in post-mitotic cells, with favorable release from mc-CR8C likely contributing
to enhanced efficacy over l-CR8C. Gene expression still limits non-viral efforts,51 as can be
observed by comparison to hydrodynamic injection; however, this formulation presents as a
much less invasive alternative and, to our knowledge, it is the most effective synthetic
vector for liver gene transfer.
Materials
1,2-distearoyl-sn-glycero-3-phosphatidylethanolamine-N-[succinyl(polyethylene
glycol)-2000]-N-hydroxysuccinimide (DSPE-PEG2000-NHS) was purchased from NOF
Corporation (Tokyo, Japan). Radioactive 111InCl3 in 0.05 N HCl was purchased from
PerkinElmer Inc. and utilized immediately upon received. DSPE-PEG2000-galactose was
synthesized through the conjugation of 10 eq. 4-aminophenyl β-D-galactopyranoside and 1
eq. of DSPE-PEG2000-NHS in PBS buffer, followed by chloroform extraction and dialysis
against water using a MWCO 1,000 dialysis tube. All other lipids were purchased from
Avanti Polar Lipids, Inc. (Alabaster, AL). Peptides were purchased from Elim
Biopharmaceuticals Inc. (Hayward, CA); monocyclic abbreviated to mc, linear abbreviated
to l. A FAM and Cy3 labeling kits were purchased from Mirus Bio LLC. (Madison, WI).
SYBR® Green I nucleic acid gel stain (S7585) was purchased from Invitrogen (Grand
Island, NY, USA). Luciferin was purchased from Promega Corporation (Madison, WI).
Plasmids encoding tdTomato red fluorescence protein (RFP) or firefly luciferase (Luc)
driven by the cytomegalovirus promoter were custom prepared by Bayou Biolabs (Harahan,
LA). All other chemicals were obtained from Sigma-Aldrich (St. Louis, MO) and used
without further purification.
Six-week-old C57BL/6 female mice (appx. 18 grams each) were purchased from Charles
River Laboratories (Wilmington, MA). All work performed on animals was in accordance
with and approved by the University of North Carolina Institutional Animal Care and Use
Committee.
Methods
Preparation and Characterization of LCP Loaded with DNA
LCP was prepared using a modified protocol.35 Two separate microemulsions (20 mL each)
were prepared of Igepal 520 and cyclohexane (3:7 v:v) and placed under stirring. DNA (60
µg) was added to 600 IL of 2.5 M CaCl2, whose pH had been titrated above 7 with NaOH.
To this solution, octaarginine peptides were added at an N:P ratio of 2:1. A Na2HPO4
solution (600 IL, 12.5 mM, pH 9) was also prepared, as was 250 IL of 20 mM DOPA (in
CHCl3). To one emulsion, the calcium phase was added, while to the other, both the
phosphate solution and DOPA were added; both emulsions were left to stir for 20 minutes.
The emulsions were then mixed, and left to stir an additional 20 minutes. An equal volume
of 100% EtOH was added to disrupt the emulsion, and the mixture was centrifuged at
10,000g for 20 minutes. After decanting the supernatant, the precipitate was washed twice
thereafter with 100% EtOH to remove traces of Igepal and/or cyclohexane. The precipitate
was then dried under N2, and resuspended in CHCl3. This solution was centrifuged at 6000
rpm for 5 minutes for the removal of large aggregates, and the supernatant containing the
LCP “cores” (DNA and peptide entrapped within a calcium phosphate nanoprecipitate,
supporting and surrounded by a lipid monolayer of DOPA) was recovered.
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To characterize DNA entrapment efficiency, firefly luciferase cDNA was labeled with Cy3
(Mirus LabelIT kit, Mirus Bio, Madison, WI) according to manufacturer instructions. Such
Cy3-DNA was formulated into the LCP cores, after which recovery was assessed via
fluorescence spectrometry. 111In-labeled LCP cores were prepared as described
previously,36 with the addition of 111InCl3 into the CaCl2 solution of the calcium emulsion.
Upon co-precipitation of the two emulsions, 111In-labeled LCP cores were collected as
described above, with centrifugation in CHCl3 removing aggregates containing 111In. The
final LCP cores encapsulated 85% of 111In.
LCP was produced through desiccation of a mixture of free lipids and cores (2.5:1 ratio of
total free lipids to DOPA) and subsequent rehydration. 35 mol% DOTAP, 35 mol%
cholesterol, and 30 mol% DSPE-PEG2000 (or 25 mol% DSPE-PEG and 5 mol% DSPE-
PEG-Gal) were utilized as outer leaflet lipids. Zeta potential and particle size of LCP was
measured using a Malvern ZetaSizer Nano Series (Westborough, MA). TEM images of LCP
were acquired using a JEOL 100CX II TEM (JEOL, Japan).
Pharmacokinetics, Biodistribution, and Intracellular Distribution of Cy3-DNA Delivered by
LCP
LCP containing Cy3-DNA, both untargeted and targeted via galactose ligands (LCP-PEG
and LCP-Gal, respectively, 0.2 mg/kg DNA dose), were injected (0.2 mL, balanced in
osmolarity with the addition of dextrose) into 6-week-old C57/BL female mice through the
tail vein. Liver tissues were frozen in OCT compound for sectioning. Liver sections (10 µm)
were fixed with cold acetone, washed in PBS, and incubated for 5 min with fluorescein
isothiocyanate (FITC)-labeled phalloidin in PBS. The sections were stained with DAPI prior
to mounting with Fluor-mount G (Southern Biotech), and imaged on a Leica SP2 confocal
microscope. UV, Cy3, and FITC filters were set up to image nuclei, intracellular DNA
distribution, and actin, respectively.
Pharmacokinetics and quantitative biodistribution were further determined via
coencapsulation with 111In (incorporated into the calcium emulsion during formulation) in
the nanoprecipitate. Such methods have been utilized previously to accurately determine
LCP biodistribution.36 Six-week-old C57BL/6 female mice (6 mice utilized for each group)
were injected individually (0.2 mL, balanced in osmolarity with the addition of dextrose)
with LCP at 0.1 mg DNA/kg, corresponding to a dose of 8x106 cpm/kg of 111In. For
pharmacokinetic analysis, blood was recovered at various time points (20, 90, 200, 390, 480,
600, and 720 minutes) via retro-orbital bleed. For biodistribution analysis, six and 12 h after
the administration of LCP, the blood and major organs were collected (6 mice utilized for
each time point). Radioactivity in the blood and tissues in both studies was measured using a
γ-counter. Analysis was conducted under a two-compartment model utilizing Phoenix
WinNonlin (Version 6.3, Pharsight Corporation; Mountain View, CA, USA).
In Vivo Gene Expression
Several groups of LCPs containing cDNA encoding tdTomato red fluorescence protein
(RFP) or firefly luciferase (Luc) were injected (0.2 mL, balanced in osmolarity with the
addition of dextrose) into 6-week-old C57BL/6 female mice (0.3 mg DNA/kg, 3 mice
utilized for each group) through the tail vein. Hydrodynamic injection was conducted by
rapid injection of a 1.6 mL solution of equal DNA dose in PBS. The major organs of the
RFP-transfected mice were harvested 24 h post-injection and visualized using a Kodak in
vivo imaging system FX Pro (Kodak, Rochester, NY) at ex/em = 550/600 nm. For
quantitative analysis of gene expression via luciferase activity, lysis buffer (0.1 M Tris-HCl,
2 mm EDTA, 0.1% Triton X-100, pH 7.8) was added to each whole organ (1mL per kidney,
spleen, lung, or heart; 15 mL per liver). Each organ was homogenized for 30 s, and
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homogenates were then centrifuged at 4°C for 10 min at 13,000 g. Total protein
concentration in the lysate was determined through a bicinchoninic acid protein assay kit
(BCA Protein Assay Kit, Pierce, Rockford, IL, USA). Ten microliters of each homogenate
supernatant were mixed with 90 microliters of luciferase assay reagent (Luciferase Assay
System, Promega Co., Madison, WI) and the luminescence intensity was measured via plate
reader (Bioscan Inc., Washington DC) for 1 second. The activity of luciferase is shown as
the luminescence intensity per milligram of protein.
DNA Condensation and Release from CR8C
DNA condensation refers to an inhibition of the DNA-intercalated SYBR green fluorescence
signal in the presence of either l-CR8C or mc-CR8C peptides. The assay was carried out in
1.5 mL Eppendorf tubes, where 10 µL of SYBR Green (10,000 dilution from stock) and 10
µL of pDNA (100 ng/µL) in 1 mL of 100 mM Tris-HCl (pH 8.0) were mixed and incubated
in the dark for 5 min at room temperature. 20 µL of peptide solutions corresponding to
different charge ratios were subsequently added, followed by incubation in the dark for 15
min. Two controls were prepared without peptide added. Fluorescence signals were recorded
at a 497/520 excitation/emission (fluorescence spectrometer, Perkin-Elmer, Waltham, USA),
with the control values taken as maximum (i.e. 100%). The inhibition in fluorescence signal
was calculated at increasing charge ratios and plotted as percentage of maximum.
For DNA release, the DNA-peptide complexes (10 µL of 100 ng/µL pDNA in each case)
were prepared at a charge ratio 4 and incubated with 10 µL of SYBR Green (10,000 dilution
from stock) in 1 mL of 100 mM Tris-HCl buffer (pH 8.0) for 30 min at room temperature.
30 µL of hyaluronic acid solution were added to the different tubes of DNA-peptide
complexes with SYBR green at increasing amounts. Three controls (pDNA with SYBR
green, SYBR green alone, and hyaluronic acid with SYBR green) were also prepared. The
fluorescence was recorded as described in the condensation section. The fluorescence value
of pDNA-peptide complexes without any hyaluronic acid was taken as 100%, and the
relative percentage increase in fluorescence signal was calculated at increasing
concentration of hyaluronic acid solutions in terms of charge ratio over the negative charges
of DNA.
Toxicity and Pathology Studies
Twenty-four hours after mice were treated with luciferase DNA and mc-CR8Cloaded LCP
(0.4 mg DNA/kg) (three mice utilized for each group), serum was obtained from the mice
via retro-orbital bleed and centrifugation. Hepatic and renal damage was assessed by
measuring the levels of AST, ALT and BUN in the serum samples. These measurements
were quantified by the Animal Clinical Chemistry and Gene Expression Laboratories at
UNC Chapel Hill. An ELISA assay kit (BD Biosciences, San Diego, CA) was used to
perform a cytokine induction assay, providing the IL-6, IL-12, IFN-γ and TNF-α levels in
the mouse serum. Further, the major organs of each mouse were collected, fixed, and
processed thereafter for H&E staining. Images of tissue sections were collected using a
Nikon light microscope with 10X objective. 95% CI were derived from the technical data
sheet C57BL/6 Mouse Hematology (North American Colonies, January 2008 – December
2011), Charles River Laboratories (Wilmington, MA).
Statistical Analysis
Statistical analysis in luciferase activity comparisons was conducted using Bonferroni-
corrected t-tests. p < 0.0125 was considered significant.
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Abbreviations
MEND Multifunctional Envelope-Type Nanodevices
CaP calcium phosphate
LCP Liposome Calcium Phosphate
DOPA 1,2-dioleoyl-sn-glycero-3-phosphate
DOTAP 1,2-dioleoyl-3-trimethylammonium-propane












RFP tdTomato red fluorescence protein
Luc firefly luciferase.
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(a) Representative multifunctional features of membrane-core LCPs consist of calcium
phosphate cores encapsulating DNA and octaarginine peptides, and an asymmetric lipid
membrane functionalized with galactose ligands on a stealth PEG layer. (b) TEM image of
LCP cores loaded with DNA and octaarginine peptides (scale bar: 50 nm). (c) TEM image
of final LCPs, stained with uranyl acetate (scale bar: 100 nm).
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(a) Serum kinetics and (b, c) biodistribution of LCP loaded with luciferase DNA and mc-
CR8C (with or without galactose) in which LCP was labeled with 111In.
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Intracellular Cy3-DNA fluorescence distribution in cryo-sections of liver tissues from
C57BL/6 mice treated with LCP-CtrDNA-Gal, LCP-(Cy3-DNA)-Gal, LCP-(Cy3-DNA+mc-
CR8C)-Gal, LCP-(Cy3-DNA+l-CR8C)-Gal, and hydrodynamic (HD) injection 6 hours after
injection. Top images are fluorescence overlay of red from Cy3-DNA, blue from DAPI-
stained nuclei, and green from FITC-labeled Phalloidin-stained actin; bottom images are
Cy3-DNA fluorescence only. Inset images are an increased magnification, to better illustrate
intranuclear Cy3-DNA fluorescence. Monocyclic abbreviated to mc, linear abbreviated to l.
Scale bar: 25 µm.
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Transgene expression in the major organs of C57BL/6 mice 24 h after intravenous injection
of plasmid formulated in different groups of LCP (plasmid dose: 0.3 mg/kg). (a)
Comparison of expressed RFP fluorescence, as determined with a Kodak IVIS system (ex/
em: 550/600 nm). Control DNA was a luciferase plasmid. (b) Comparison of expressed
luciferase in the liver. All are compared with the group of Gal-targeted LCP containing mc-
CR8C. N = 3 per group. **: p < 0.0125. (c) comparison of expressed luciferase in various
major organs after the administration of plasmid formulated in the Gal-targeted LCP
containing mc-CR8C.
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Condensation and de-condensation of DNA/CR8C complexes. (a) Fluorescence quenching
associated with the exclusion of DNA-SYBR Green by mc-CR8C and l-CR8C at different
charge ratios (+/−, CR8C over DNA). (b) Fluorescence recovery through the dissociation of
DNA-CR8C complexes driven by hyaluronic acid (HA) at different charge ratios (−/−, HA
over DNA).
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Histopathology of H&E-stained major organs from C57BL/6 mice (top) without treatment
and (bottom) after treatment with LCP-(RFP+mc-CR8C)-Gal. Scale bar: 100 µm.
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Scheme 1. Proposed Mechanism for Intracellular Delivery of DNA by LCP
(a) ASGPR-mediated endocytosis, elicited by binding to galactose ligands on LCP, supports
internalization into hepatocytes. (b) PEGylation shedding is driven by a decrease in
endosomal pH.37 (c) Dissolution of the calcium phosphate core and breakdown of the lipid
membrane promotes (d) disruption of the endosome in a cationic lipid-mediated manner. (e)
Nuclear import of DNA is thought to be mediated by cysteine-flanked octaarginine peptides.
(f) DNA is released in the nucleus for active transcription.
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Table 1






LCP-DNA-Gal 52 ± 8 5 ± 2 0.18
LCP-(DNA+mc-CR8C)-Gal 57 ± 10 10 ± 3 0.24
LCP-(DNA+l-CR8C)-Gal 56 ± 11 8 ± 3 0.23
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Table 2
Kinetic analysis based on recovery of LCP-associated 111In radioactivity. Data are reported as estimate ±
standard error. CLdist = distribution clearance; Vblood = volume of distribution in the circulation compartment;
t1/2dist = distribution-phase half-life (estimated as Ln(2)*Vblood /CLdist, assuming unidirectional initial
distribution from the circulation compartment to the peripheral compartment [i.e. liver and/or spleen]); t1/2elim
= elimination-phase half-life (estimated from a linearization of the terminal phase kinetic profile).
Kinetic Analysis Cldist (mL/hr) Vblood (mL) t1/2 dist (hr) t1/2 elim (hr)
LCP-Gal 4.71 ± 0.22 4.16 ± 0.04 0.61 6.80
LCP-PEG 0.35 ± 0.15 1.24 ± 0.06 2.46 5.78
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